Loading...
Back to narrative

Update shared on08 Oct 2025

Fair value Decreased 1.93%
AnalystConsensusTarget's Fair Value
US$72.00
29.3% undervalued intrinsic discount
22 Oct
US$50.87
Loading
1Y
-26.2%
7D
-4.0%

Analysts have modestly reduced their price target for Ryan Specialty Holdings, citing commercial property growth headwinds and a slight decrease in projected revenue growth. The fair value estimate is now lowered by approximately $1.42 to $72.00 per share.

Analyst Commentary

Recent Street research on Ryan Specialty Holdings reflects a mix of optimism and caution regarding the company's near-term outlook and valuation. Analysts recognize the company's robust growth characteristics as well as sector-wide headwinds affecting pricing and expansion in commercial property and casualty lines. Below are the key takeaways from their commentaries:

Bullish Takeaways

  • Bullish analysts view Ryan Specialty's organic and inorganic growth prospects as strong, suggesting the recent share price pullback may be overdone relative to the company’s fundamentals.
  • Margins are expected to continue outpacing those of sector peers, supporting the case for a premium valuation.
  • Earnings resiliency is expected even as pricing tailwinds ease, with upside potential noted versus other underwriters and brokers.
  • The company's valuation is seen as more attractive following share price declines, placing it in line with broader industry peers and setting the stage for potential re-rating.

Bearish Takeaways

  • Bearish analysts caution that commercial property growth is facing notable headwinds due to a slowdown in both the primary insurance and reinsurance sub-sectors.
  • Slower revenue and property pricing growth are contributing to more conservative price target adjustments and expectations.
  • Increased competition and more selective underwriting across the insurance sector could challenge the pace of expansion and margin growth going forward.
  • Sector-wide trends, such as softened reinsurance pricing and the transition away from a multi-year hard market, add further uncertainty to near-term forecasts and valuations.

What's in the News

  • Ryan Specialty Holdings is actively seeking M&A opportunities, with management reaffirming that mergers and acquisitions remain the company's top capital allocation priority. The CFO highlighted the firm's strong balance sheet and willingness to expand leverage for strategic deals. (Key Developments)
  • The company has lowered its full-year 2025 organic revenue growth guidance to a range of 9.0% to 11.0%, down from its previous outlook of 11% to 13.0%. (Key Developments)

Valuation Changes

  • Fair Value Estimate: Lowered from $73.42 to $72.00 per share. This reflects a moderate decrease in the company’s assessed intrinsic value.
  • Discount Rate: Slightly reduced from 6.82% to 6.78%, indicating a minor change in perceived risk.
  • Revenue Growth: Projected long-term revenue growth rate decreased from 17.60% to 16.82%.
  • Net Profit Margin: Margins have increased from 23.75% to 24.20%, suggesting improved profitability expectations.
  • Future P/E Ratio: Notably declined from 23.72x to 11.30x. This signals a significant shift in forward valuation multiples.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.